Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following conditions or symptoms are excluded:
• •Known hypersensitivity to interferons or other exogenous lymphokine.
• •History of cardiac abnormality or disease.
• •History of hypertension.
• •Patients with the following are excluded:
• •Known hypersensitivity to interferons or other exogenous lymphokine.
• •History of cardiac abnormality or disease.
• •History of hypertension.
• •Prior Medication:
• •Excluded within 4 weeks of study entry:
• •Corticosteroids.
• •Anti-inflammatory medication (except aspirin).
• •Changes in the dose of anti-mycobacterial drugs.
• •Immune agents.
• •Prior Treatment:
• •Excluded within 4 weeks of study entry:
• •Radiotherapy.
• •Risk Behavior:
• •Excluded:
• •Intravenous drug abuse.